Piramal Pharma’s Critical Care Division Launches Chlorpromazine Hydrochloride Injection in the U.S.

Piramal Pharma announced on Wednesday, January 22, that its division, Piramal Critical Care (PCC), has launched Chlorpromazine Hydrochloride for Injection, USP in the United States. This marks an important addition to PCC’s growing portfolio of generic injectable products.

The product will be available in two vial formats: 25 mg/1 mL and 50 mg/2 mL, providing greater flexibility for healthcare providers and expanding PCC’s offerings in critical care.

Recent Achievements in Generic Injectables

The launch of Chlorpromazine Hydrochloride for Injection follows a series of recent introductions by PCC in the generic injectables market. In 2024, the company successfully launched the first-to-market generic of Edaravone IV Infusion, a milestone that further strengthened its market presence.

These efforts build on PCC’s earlier successes in 2023, including the launches of Pantoprazole Sodium for Injection, USP, and Doxycycline for Injection, USP, both of which contributed to broadening its portfolio of critical care products.

Commitment to Critical Care Business

Piramal Critical Care continues to focus on expanding its product pipeline in the U.S. and other global markets. This latest launch underscores the division’s dedication to enhancing access to high-quality, affordable injectable medications that address critical healthcare needs.

The company remains committed to delivering innovative solutions in the critical care segment, with a strong emphasis on addressing unmet medical demands through its robust portfolio.

Stock Performance 

On January 23, 2025, Piramal Pharma share price traded up by 2.20% at 10:55 AM (IST) at ₹248 Piramal Pharma’s share price reached a 52-week high of ₹307.85 on November 06, 2024, and a 52-week low of ₹114.45 on March 15, 2024. As per BSE, the total traded volume for the stock stood at 0.88 lakh shares with a turnover of ₹2.16 crore.

At the current price, Piramal Pharma shares are trading at a price-to-earnings (P/E) ratio of 50.05x, based on its trailing 12-month earnings per share (EPS) of ₹4.85, and a price-to-book (P/B) ratio of 4.58, according to exchange data.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.